These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34988523)

  • 1. Sacubitril/valsartan versus angiotensin inhibitors and arrhythmia endpoints in heart failure with reduced ejection fraction.
    Fernandes ADF; Fernandes GC; Ternes CMP; Cardoso R; Chaparro SV; Goldberger JJ
    Heart Rhythm O2; 2021 Dec; 2(6Part B):724-732. PubMed ID: 34988523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Angiotensin Receptor-Neprilysin Inhibitors on Arrhythmias in Patients with Heart Failure: A Systematic Review and Meta-analysis.
    Mujadzic H; Prousi GS; Napier R; Siddique S; Zaman N
    J Innov Card Rhythm Manag; 2022 Sep; 13(9):5164-5175. PubMed ID: 36196235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term impact of angiotensin receptor-neprilysin inhibitor based on short-term treatment response in heart failure.
    Park HK; Park JS; Kim MS; Lee E; Choi H; Park YJ; Park BE; Kim HN; Kim N; Bae MH; Lee JH; Park HS; Cho Y; Jang SY; Yang DH
    ESC Heart Fail; 2023 Dec; 10(6):3430-3437. PubMed ID: 37705397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices.
    de Diego C; González-Torres L; Núñez JM; Centurión Inda R; Martin-Langerwerf DA; Sangio AD; Chochowski P; Casasnovas P; Blazquéz JC; Almendral J
    Heart Rhythm; 2018 Mar; 15(3):395-402. PubMed ID: 29146274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis.
    Rohde LE; Chatterjee NA; Vaduganathan M; Claggett B; Packer M; Desai AS; Zile M; Rouleau J; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    JACC Heart Fail; 2020 Oct; 8(10):844-855. PubMed ID: 32919916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacubitril/valsartan and arrhythmic burden in patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis.
    Pozzi A; Abete R; Tavano E; Kristensen SL; Rea F; Iorio A; Iacovoni A; Corrado G; Wong C
    Heart Fail Rev; 2023 Nov; 28(6):1395-1403. PubMed ID: 37380925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up.
    Paolini C; Mugnai G; Dalla Valle C; Volpiana A; Ferraglia A; Frigo AC; Bilato C
    Int J Cardiol Heart Vasc; 2021 Aug; 35():100821. PubMed ID: 34179333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence?
    Vecchi AL; Abete R; Marazzato J; Iacovoni A; Mortara A; De Ponti R; Senni M
    Heart Fail Rev; 2022 Jan; 27(1):103-110. PubMed ID: 32556671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
    Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W
    Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study.
    Hsiao FC; Lin CP; Yu CC; Tung YC; Chu PH
    Front Cardiovasc Med; 2022; 9():794707. PubMed ID: 35360037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of sacubitril-valsartan on the incidence of atrial fibrillation: A meta-analysis.
    Mohammad Z; Ahmad J; Sultan A; Penagaluri A; Morin D; Dominic P
    J Cardiovasc Electrophysiol; 2023 Apr; 34(4):1037-1042. PubMed ID: 36871177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from ramipril to sacubitril/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction.
    Okutucu S; Sabanoglu C; Yetis Sayin B; Aksoy H; Bursa N; Oto A
    Acta Cardiol; 2020 Feb; 75(1):20-25. PubMed ID: 30513267
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea.
    Park SK; Hong SH; Kim H; Kim S; Lee EK
    Clin Ther; 2019 Jun; 41(6):1066-1079. PubMed ID: 31101372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
    Chin KL; Zomer E; Wang BH; Liew D
    Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction.
    Khariton Y; Fonarow GC; Arnold SV; Hellkamp A; Nassif ME; Sharma PP; Butler J; Thomas L; Duffy CI; DeVore AD; Albert NM; Patterson JH; Williams FB; McCague K; Spertus JA
    JACC Heart Fail; 2019 Nov; 7(11):933-941. PubMed ID: 31521679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials.
    Bao J; Kan R; Chen J; Xuan H; Wang C; Li D; Xu T
    Pharmacol Res; 2021 Jul; 169():105573. PubMed ID: 33766629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between sacubitril/valsartan initiation and real-world health status trajectories over 18 months in heart failure with reduced ejection fraction.
    Thomas M; Khariton Y; Fonarow GC; Arnold SV; Hill L; Nassif ME; Chan PS; Butler J; Thomas L; DeVore AD; Hernandez AF; Albert NM; Patterson JH; Williams FB; Spertus JA
    ESC Heart Fail; 2021 Aug; 8(4):2670-2678. PubMed ID: 33932120
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.